Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 37, Issue 6, 2018, Pages 1113-1118

  Bjornson, Candice ^a   Chan, Parco ^b,c   Li, Abby ^b   Paes, Bosco ^d   Lanctôt, Krista L ^b,c   Mitchell, Ian ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Cystic fibrosis; Outcomes; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ALBERTA; ARTICLE; ARTIFICIAL VENTILATION; ASSISTED VENTILATION; BIRTH WEIGHT; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HOSPITALIZED INFANT; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; INFANT DISEASE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; NEWBORN SCREENING; NONHUMAN; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; ADVERSE DRUG REACTION; COMPLICATION; DRUG EFFECT; NEWBORN; OUTCOME ASSESSMENT; REGISTER; VIROLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; COHORT STUDIES; CYSTIC FIBROSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; PALIVIZUMAB; PATIENT OUTCOME ASSESSMENT; REGISTRIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RETROSPECTIVE STUDIES;

EID: 85044239757     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-018-3225-7     Document Type: Article

References (31)

1. Website:.http://www.cysticfibrosis.ca/wp-content/uploads/2013/10/The-Facts-About-Cystic-Fibrosis.pdf. Accessed 18 Jan 2018
2. Stick SM, Brennan S, Murray C, Douglas T, von Ungern-Sternberg BS, Garratt LW, Gangell CL, De Klerk N, Linnane B, Ranganathan S, Robinson P, Robertson C, Sly PD (2009) Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 155(5):623–628
3. Sly PD, Brennan S, Gangell C, De Klerk N, Murray C, Mott L, Stick SM, Robinson PJ, Robertson CF, Ranganathan SC (2009) Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 180(2):146–152
4. Collins CL, Pollard AJ (2002) Respiratory syncytial virus infections in children and adults. J Inf Secur 45(1):10–17
5. Figueras-Aloy J, Manzoni P, Paes B, Simões EAF, Bont L, Checchia PA, Faroux B, Carbonell-Estrany X (2016) Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther 5(4):417–452
6. Paes B, Fauroux B, Figueras-Aloy J, Bont L, Checchia PA, Simões EAF, Manzoni P, Carbonell-Estrany X (2016) Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with chronic lung disease. Infect Dis Ther 5(4):453–471
7. Checchia PA, Paes B, Bont L, Manzoni P, Simões EAF, Fauroux B, Figueras-Aloy J, Carbonell-Estrany X (2017) Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with congenital heart disease. Infect Dis Ther 6(1):37–56
8. Manzoni P, Figueras-Aloy J, Simões EAF, Checchia PA, Fauroux B, Bont L, Paes B, Carbonell-Estrany X (2017) Defining the incidence and associated morbidity and mortality of severe respiratory syncytial virus infection among children with chronic diseases. Infect Dis Ther 6(3):383–411
9. Arnold SR, Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, Langley JM, McDonald J, MacDonald NE, Mitchell I (1999) Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatr Infect Dis J 18(10):866–869
10. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ (1988) Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 113(5):826–830
11. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, Piedra PA (1999) Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 103(3):619–626
12. Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, Saxena S (2014) Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS One 9(2):e89186
13. Kristensen K, Hjuler T, Ravn H, Simoẽs EAF, Stensballe LG (2012) Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis 54(6):810–817
14. Resch B (2017) Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother 13(9):2138–2149
15. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102(3 Pt 1):531–537
16. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143(4):532–540
17. Feltes TF, Sondheimer HM, Tulloh RMR, Harris BS, Jensen KM, Losonsky GA, Griffin MP (2011) A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 70(2):186–191
18. Paes B, Mitchell I, Li A, Harimoto T, Lanctôt KL (2013) Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol 2013:917068
19. Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL (2015) Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian registry of Palivizumab. Pediatr Infect Dis J 34(12):e290–e297
20. Gaboli M, de la Cruz ÒA, de Agüero MI, Moreno-Galdó A, Pérez GP, de Querol MS (2014) Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study. Pediatr Pulmonol 49(5):490–502
21. Sánchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L (2013) Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. Allergol Immunopathol (Madr) 43(3):298–303
22. Groves HE, Jenkins L, Macfarlane M, Reid A, Lynn F, Shields MD (2016) Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland. Pediatr Pulmonol 51(4):379–385
23. Manzoni P, Paes B, Lanctot KL, Dall’Agnola A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T, Li A (2017) Outcomes of infants receiving Palivizumab prophylaxis for respiratory syncytial virus in Canada and Italy: an international, prospective cohort study. Pediatr Infect Dis J 36(1):2–8
24. Metz J, Eber E, Resch B (2017) Respiratory syncytial virus infection-associated hospitalization rates in infants and children with cystic fibrosis. Pediatr Infect Dis J 36(6):545–548
25. Linnane B, Kiernan MG, O’Connell NH, Kearse L, Dunne CP (2015) Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland. Multidiscip Respir Med 10:32
26. Winterstein AG, Eworuke E, Xu D, Schuler P (2013) Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Pediatr Pulmonol 48(9):874–884
27. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S (2008) Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 43(2):169–174
28. Augustine EF, Adams HR, Mink JW (2013) Clinical trials in rare disease: challenges and opportunities. J Child Neurol 28(9):1142–1150
29. The needs of the few (2010) Nature 466(7303):160
30. Robinson KA, Odelola OA, Saldanha IJ (2016) Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 7:CD007743
31. Website: http://www.cysticfibrosis.ca/de/action/download?downloads=16&file=dl_2016+Registry+Annual+Data+Report.pdf. Accessed 18 Jan 2018